Literature DB >> 10999575

Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures.

B E Benson1, M Mathiason, B Dahl, K Smith, M M Foley, L A Easom, A Y Butler.   

Abstract

Toxicities and medical outcomes associated with nefazodone poisoning were characterized using national poisoning data from the American Association of Poison Control Centers and through prospective collection of additional data elements. Nefazodone exposures involving concomitant agents were excluded. There were 1,338 human exposures included in the final data analysis. Seventy-five percent of exposures were acute and 20% involved children < 13 years. Twenty-five percent of patients remained asymptomatic. There were no deaths. No dose response relationship was evident in the 45 cases where estimated doses were available. The most common manifestations were drowsiness (17.3% of all patients), nausea (9.7%), and dizziness (9.5%). The most common serious clinical effect was hypotension (1.6%). The median onset time for symptoms was 1.75 hours. Manifestations resolved within 8 to 24 hours. Most patients were treated with only gastrointestinal decontamination. No patients required intubation, mechanical ventilation, or vasopressors. Nefazodone appears to be of low toxicity during poisonings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999575     DOI: 10.1053/ajem.2000.9287

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  Third-generation antidepressants: do they offer advantages over the SSRIs?

Authors:  J S Olver; G D Burrows; T R Norman
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Characteristics and trends of emergency patients with drug overdose in Osaka.

Authors:  Yoshie Kubota; Kohei Hasegawa; Hirokazu Taguchi; Tetsuhisa Kitamura; Chika Nishiyama; Taku Iwami; Tatsuya Nishiuchi; Atsushi Hiraide
Journal:  Acute Med Surg       Date:  2015-03-15

Review 3.  'Atypical' antidepressants in overdose: clinical considerations with respect to safety.

Authors:  Nicholas A Buckley; Thomas A Faunce
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.